Confo Therapeutics Press Release
July 29, 2024

Confo Therapeutics Announces EUR 60M Series B Financing to Advance Pipeline of Novel GPCR-Modulating Therapies into Clinical Development

• Proceeds to support Phase…
read more
Confo Therapeutics Press Release
August 30, 2023

Confo Therapeutics Appoints Dieter Weinand, Former CEO of Bayer Pharmaceuticals, as Independent Chairman

Ghent, Belgium – August 29,…
read more
Confo Therapeutics Press Release
June 15, 2023

Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera

• Collaboration to make use…
read more
Confo Therapeutics Press Release
March 30, 2023

Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases

Collaboration to make use of…
read more
Confo Therapeutics Press Release
March 2, 2023

Confo Therapeutics Announces Global Licensing Agreement with Lilly for Peripheral Pain Candidate, CFTX-1554

Confo to receive upfront and…
read more
Confo Therapeutics Press Release
March 10, 2022

Confo Therapeutics Doses First Subjects in Phase 1 Clinical Trial of CFTX-1554 for the Treatment of Neuropathic Pain

Confo Therapeutics Doses First Subjects…
read more
Confo Therapeutics Press Release
December 16, 2021

Confo Therapeutics Expands Patent Estate for ConfoBody®-based GPCR Screening Platform

Confo Therapeutics Expands Patent Estate…
read more
Confo Therapeutics Press Release
November 30, 2021

Confo Therapeutics Enters Collaborative Agreement with Regeneron

Confo Therapeutics Enters Collaborative Agreement…
read more
Confo Therapeutics Press Release
June 11, 2021

Confo Therapeutics Establishes Medical Advisory Board

Confo Therapeutics Establishes Medical Advisory…
read more
Confo Therapeutics Press Release
October 15, 2020

Confo Therapeutics Announces Selection of First Product Candidate and Initiation of Pre-Clinical Development

Confo Therapeutics Announces Selection of…
read more